These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 1692896)

  • 41. Is there a role for pure antiandrogens in the treatment of advanced prostatic cancer?
    Pavone-Macaluso M; Serretta V; Daricello G; Pavone C; Cacciatore M; Romano C; Cavallo N
    Prog Clin Biol Res; 1990; 350():149-57. PubMed ID: 2201041
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum testosterone level to predict the efficacy of sequential use of antiandrogens as second-line treatment following androgen deprivation monotherapy in patients with castration-resistant prostate cancer.
    Hashimoto K; Masumori N; Hashimoto J; Takayanagi A; Fukuta F; Tsukamoto T
    Jpn J Clin Oncol; 2011 Mar; 41(3):405-10. PubMed ID: 20947624
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adjuvant and salvage radiotherapy after radical prostatectomy.
    Höcht S; Wiegel T; Schostak M; Hinkelbein W
    Onkologie; 2002 Jun; 25(3):201-6. PubMed ID: 12119453
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Secondary hormonal manipulation.
    Merseburger AS; Belka C; Behmenburg K; Stenzl A
    Front Radiat Ther Oncol; 2008; 41():93-102. PubMed ID: 18544990
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chemical castration and anti-androgens induce differential gene expression in prostate cancer.
    Lehmusvaara S; Erkkilä T; Urbanucci A; Waltering K; Seppälä J; Larjo A; Tuominen VJ; Isola J; Kujala P; Lähdesmäki H; Kaipia A; Tammela TLj; Visakorpi T
    J Pathol; 2012 Jul; 227(3):336-45. PubMed ID: 22431170
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hormonal treatment in prostate cancer.
    Zbranca E; Preda C
    Endocrinologie; 1991; 29(1-2):91-7. PubMed ID: 1803495
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.
    Fu AZ; Tsai HT; Haque R; Yood MU; Cassidy-Bushrow AE; Van Den Eeden SK; Keating NL; Smith MR; Zhou Y; Aaronson DS; Potosky AL
    J Urol; 2017 Jun; 197(6):1448-1454. PubMed ID: 28007467
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Endocrine therapy of breast and prostate cancer.
    Manni A
    Endocrinol Metab Clin North Am; 1989 Jun; 18(2):569-92. PubMed ID: 2663486
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.
    Nair B; Wilt T; MacDonald R; Rutks I
    Cochrane Database Syst Rev; 2002; (1):CD003506. PubMed ID: 11869665
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intermittent androgen deprivation therapy may prolong the duration of androgen dependence of well-differentiated prostate cancer.
    Kaneko Y; Maekawa S; Arakaki R; Okada Y; Terada N; Nishimura K
    Hinyokika Kiyo; 2006 Apr; 52(4):259-64. PubMed ID: 16686352
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Endocrine therapy for localized or locally advanced prostate cancer].
    Fontaine E; Ruffion A; Staerman F
    Prog Urol; 2004 Jun; 14(3):433-6. PubMed ID: 15373195
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Adjuvant chemotherapy and/or hormone therapy after radical prostatectomy for high-risk prostate cancer].
    Paule B; de la Taille A
    Prog Urol; 2005 Apr; 15(2):208-12. PubMed ID: 15999594
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Enhancing the efficacy of radical prostatectomy in locally advanced prostate cancer.
    Altwein JE
    Urol Int; 1998; 60 Suppl 2():2-10; discussion 35. PubMed ID: 9607552
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms.
    Schally AV; Redding TW; Comaru-Schally AM
    Cancer Treat Rep; 1984 Jan; 68(1):281-9. PubMed ID: 6362868
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term use of combined radiation therapy and hormonal therapy in the management of stage D1 prostate cancer.
    Robnett TJ; Whittington R; Malkowicz SB; Brereton HD; Van Arsdalen K; Drach G; Wein AJ
    Int J Radiat Oncol Biol Phys; 2002 Aug; 53(5):1146-51. PubMed ID: 12128114
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment options in androgen-independent prostate cancer.
    Lara PN; Meyers FJ
    Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intermittent hormone therapy and its place in the contemporary endocrine treatment of prostate cancer.
    Shaw G; Oliver RT
    Surg Oncol; 2009 Sep; 18(3):275-82. PubMed ID: 19269165
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The timing and extent of androgen deprivation therapy for prostate cancer: weighing the clinical evidence.
    Ginzburg S; Albertsen PC
    Endocrinol Metab Clin North Am; 2011 Sep; 40(3):615-23, ix. PubMed ID: 21889724
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Combined anti-androgen treatment in adenocarcinoma of the prostate: first use of a new therapeutically efficacious principle in hormone-dependent cancer].
    Labrie F; Dupont A; Bélanger A; Lacourcière Y; Monfette JE; Monfette G
    Ann Urol (Paris); 1986; 20(2):98-106. PubMed ID: 2940959
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
    Moreau JP; Delavault P; Blumberg J
    Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.